Stockreport

Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer [Yahoo! Finance]

ONO PHARM CO UNSP/ADR  (OPHLY) 
NASDAQ:AMEX Investor Relations: ono.co.jp/eng/investor/index.html
PDF Numab to receive upfront payment and eligible to receive additional milestone payments plus option to co-develop with profit split arrangement in the United States Ag [Read more]